Esperion Therapeutics Secures $70,000,000 New Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7707e52b-f53b-4f90-9dc8-49d51e5ef5c3&Preview=1
Date 6/26/2013
Company Name Esperion Therapeutics
Mailing Address 46701 Commerce Center Drive Plymouth, MI 48170
Company Description Esperion Therapeutics, Inc. (NASDAQ: ESPR) discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called HDL Therapy, which is based on the Company’s understanding of high-density lipoprotein, or HDL, function.